Tempest Therapeutics, Inc. filings document material-event disclosures for a clinical-stage biotechnology company developing CAR-T cell therapy and small-molecule product candidates. The company’s 8-K filings include Regulation FD presentations, press releases on TPST-2003 clinical data, annual financial results, business updates, and exhibits describing corporate presentations and pipeline activity.
The filing record also covers capital-structure and governance matters, including Nasdaq-listed common stock, Series A Junior Participating Preferred Purchase Rights, a limited-duration stockholder rights plan, equity incentive plan amendments, and listing-compliance notices. Material agreement disclosures include the completed acquisition of dual-targeting CAR-T assets and related common stock consideration.
Tempest Therapeutics filed an 8-K to share a new investor presentation outlining its oncology pipeline and clinical data. The deck highlights TPST-2003, a dual CD19/BCMA CAR-T for relapsed/refractory multiple myeloma with extramedullary disease, which showed a 100% hematologic objective response rate in 18 patients and 75.3% 12‑month progression-free survival, with manageable CRS and ICANS rates.
The presentation also details amezalpat (TPST‑1120), a first-in-class PPARα antagonist, which in a randomized Phase 1b/2 hepatocellular carcinoma study improved median overall survival to 21 months versus 15 months for atezolizumab plus bevacizumab alone, with a hazard ratio of 0.65 and higher confirmed response rates, while maintaining a similar safety profile. Tempest has regulatory alignment with FDA, EMA and China’s NMPA on a pivotal Phase 3 design and notes orphan drug and Fast Track designations for amezalpat. Additional programs include TPST‑1495 moving into an NCI-funded Phase 2 trial in familial adenomatous polyposis and multiple CAR‑T collaborations with Novatim, many of which are partner-funded.
Tempest Therapeutics CEO Matthew Angel has filed a Schedule 13D reporting a large ownership stake in the company. He beneficially owns 4,837,070 shares of common stock, representing 35.9% of Tempest’s outstanding shares immediately after an asset purchase transaction involving Erigen LLC and Factor Bioscience.
The shares were issued to Erigen as consideration for certain assets and then allocated to its equityholders, including Angel, who invested personal funds to buy his Erigen interest. Angel holds sole voting and dispositive power over all reported shares and acquired them for investment purposes, with the possibility of additional equity awards or sales over time.
The asset purchase agreement requires Tempest to file a resale registration statement for the shares issued to Erigen, and a lock-up agreement restricts transfers of 50% of Erigen’s Tempest stock for 180 days after closing. Angel, now Chief Executive Officer, President and director, states he currently has no specific plans for corporate control or structural changes beyond these disclosed arrangements.
Tempest Therapeutics, Inc. CEO, President and director Matthew Angel, also a 10% owner, reported a grant of employee stock options on February 4, 2026. He received options to purchase 269,621 shares of common stock at an exercise price of $2.38 per share, expiring on February 3, 2036.
According to the vesting schedule, 25% of the underlying shares will vest on February 4, 2027, with the remaining shares vesting in 36 equal monthly installments thereafter, subject to his continued service. Following this award, he beneficially owns 269,621 derivative securities directly.
Tempest Therapeutics CEO and President Matthew Angel, who also serves as a director and 10% owner of Tempest Therapeutics, Inc., filed an initial Form 3. The filing reports 8,268,495 shares of common stock held indirectly through Erigen LLC.
The shares are owned by Erigen LLC, where Angel is a member, and he disclaims beneficial ownership of these securities except for his proportionate pecuniary interest. This filing establishes his indirect ownership position under Section 16 reporting rules.
Tempest Therapeutics completed an asset acquisition from Erigen and Factor Bioscience, issuing 8,268,495 shares of common stock as consideration for four CAR T-cell therapy programs. Immediately afterward, prior equityholders owned about 38.7% of the company and Erigen held about 61.3%.
The company also executed a one-time warrant distribution, issuing 6,784,989 warrants, each allowing the purchase of one share of common stock at $18.48 per share in cash until February 3, 2031, subject to an effective registration statement. As of immediately after the share issuance, 13,481,070 common shares were outstanding.
Governance shifted as Geoff Nichol resigned from the board, Michael Raab was succeeded as board chair by Stephen Brady, and Brady resigned as President and CEO. Matthew (Matt) Angel, Ph.D. became President, CEO and a Class I director under a new employment agreement that includes equity awards and severance protections.
Tempest Therapeutics director Ronit Simantov received a stock option grant for 1,230 shares on January 27, 2026. The option has an exercise price of $2.94 per share and was granted at no cost. It will vest in full on the earlier of January 27, 2027, or the company’s 2026 annual stockholder meeting, provided Simantov continues serving through that date.
Tempest Therapeutics director Nichol Geoffrey received a grant of stock options on January 27, 2026. The award covers 1,230 options to buy Tempest common stock at an exercise price of $2.94 per share, all held directly.
These options will vest in full on the earlier of January 27, 2027, or the day of Tempest’s 2026 annual stockholder meeting, if Geoffrey continues to serve through that date. Following this grant, he beneficially owns 1,230 derivative securities linked to Tempest shares.
Tempest Therapeutics director receives stock option grant. Director Michael Raab was granted a stock option to purchase 1,230 shares of Tempest Therapeutics, Inc. common stock at an exercise price of $2.94 per share on January 27, 2026.
The option vests in full on the earlier of January 27, 2027 or the date of the company’s 2026 annual stockholder meeting, contingent on his continuous service through that date. Following this grant, he beneficially owns 1,230 derivative securities directly, with the option expiring on January 26, 2036.
Tempest Therapeutics director Christine A. Pellizzari reported a new stock option grant. On January 27, 2026, she was awarded an option to buy 1,230 shares of Tempest Therapeutics common stock at an exercise price of $2.94 per share, held directly.
The option vests in full on the earlier of January 27, 2027 or the day of Tempest Therapeutics' 2026 annual stockholder meeting, as long as she continues serving through that date. The option expires on January 26, 2036, and represents 1,230 derivative securities beneficially owned following the grant.
Tempest Therapeutics held its 2025 annual stockholder meeting, where investors approved several key governance and share-related proposals. Stockholders extended the company’s limited duration stockholder rights plan, keeping it in place until October 10, 2026 unless earlier redeemed or exchanged.
They approved an amendment to the Amended and Restated 2023 Equity Incentive Plan, increasing the shares available for equity awards by 1,410,000. Stockholders also approved issuing 8,268,495 shares of common stock to satisfy obligations under an asset purchase agreement with Erigen LLC and Factor Bioscience Inc., meeting Nasdaq Rule 5635 requirements.
Other items that passed included electing one Class I director, an advisory vote approving named executive officer compensation, and ratifying Ernst & Young LLP as independent auditor for the fiscal year ending December 31, 2025.